Association of emotional distress with immune checkpoint inhibition efficacy in melanoma
Introduction Emotional distress (ED) at the start of neoadjuvant immune checkpoint inhibitors (ICI) for melanoma has been linked to impaired response and survival. However, in the metastatic and adjuvant setting, the association of ED with ICI outcomes in melanoma remains unclear. Methods ED at the start of ICI was assessed in patients with melanoma between 2015 and 2025 using the validated Utrecht Symptom Diary questionnaire. Associations between ED and progression-free survival (PFS) or recurrence-free survival (RFS), overall survival (OS), and melanoma-specific survival (MSS) were analyzed using Cox regression with adjustment for possible confounders. Patients treated with anti-PD-1 monotherapy or ipilimumab + nivolumab (IPINIVO) in the metastatic setting, and patients treated with adjuvant anti-PD-1 monotherapy, were analyzed separately. Results 555 patients were included. For 169 patients treated with anti-PD-1 monotherapy in the metastatic setting, ED was associated with significantly impaired OS (HRadj 2.10, 95% CI 1.20-3.68) and MSS (HRadj 2.24, 95% CI 1.18-4.28); the association with PFS did not reach significance (HRadj 1.56, 95% CI 0.97-2.51). For 193 patients treated with IPINIVO in the metastatic setting, no associations were observed between ED and survival. In the cohort of 193 patients treated with adjuvant anti-PD-1 monotherapy, ED was significantly associated with worse RFS (HRadj 2.29, 95% CI 1.36-3.85) and OS (HRadj 2.35, 95% CI 1.05-5.30), while the association with MSS was not significant. Conclusion ED at the start of anti-PD-1 monotherapy was associated with impaired survival in melanoma patients across metastatic and adjuvant settings. ED at the start of IPINIVO was not associated with survival.
Authors
- Marijke M. Ros
- Sigrid C. J. M. Vervoort (ORCID: https://orcid.org/0000-0003-3578-3685)
- Daniëlle Zweers (ORCID: https://orcid.org/0000-0002-9143-1759)
- Anna M. Kamphuis
- Rik Jasper Verheijden (ORCID: https://orcid.org/0000-0003-1966-1063)
- Josephine J. Koldenhof (ORCID: https://orcid.org/0000-0003-4205-6611)
- E.J. van Dijk
- Luuk L J Huijts
- Karijn P M Suijkerbuijk
Institutions
- Utrecht University (NL)
- Gelre Hospitals (NL)
- University Medical Center Utrecht (NL)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1093/jnci/djag459
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00